Rationale: After the sample size of a randomized clinical trial (RCT) is set by the power requirement of its primary endpoint, investigators select secondary endpoints while unable to further adjust sample size. How the sensitivity and specificity of an instrument used to measure these outcomes, together with their expected underlying event rates, affect an RCT's power to measure significant differences in these outcomes is poorly understood.
When choosing endpoints for randomized clinical trials (RCTs), trial designers must first determine the domains of scientific and clinical interest relevant to the study intervention. A primary study endpoint such as mortality is often chosen to assess the overall benefit of a new treatment. However, additional endpoints may also be relevant, particularly if a new treatment has important risks or the potential for adverse events. These safety endpoints are often relegated to the study's secondary outcomes and given less importance in a study's design. Yet, when deciding whether a new treatment is clinically useful, a clinician must weigh both the benefits and the risks of a particular treatment before deciding whether to use it in clinical practice. Therefore, it is important that a clinical trial be designed to detect important differences in secondary outcomes or adverse events if those outcomes have the potential to tip the balance of the risk-to-benefit ratio for a particular treatment.
The matter of choosing clinical trial endpoints for certain domains of interest is complicated by the fact that some outcomes, such as physical disability or psychiatric symptoms, are not quantified directly. These outcomes must be assessed using a test or measurement instrument (e.g., a survey administered to patients) that has an imperfect ability to measure such outcomes. Often more than one validated instrument is available to measure an outcome, each with known but distinct properties-that is, different combinations of sensitivities, specificities, and implementation burdens. In clinical practice, a clinician ought to choose a particular test by weighing the importance of the condition, burden of treatment, risks associated with a false-positive or falsenegative result, and preferences of the patient. However, in a clinical trial, where the primary goal is to determine whether the risk-benefit burden of one treatment is significantly different from another, the selection of a test or instrument used to detect potential differences in a clinical endpoint should be guided on the basis of this specific goal.
As an example, the Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) RCT (www.clinicaltrials.gov identifier NCT02509078) is a multicenter, prospective, two-arm, nonblinded RCT of the effect of early neuromuscular blockade on 90-day in-hospital mortality of patients with moderate to severe acute respiratory distress syndrome (ARDS) (1) . The ROSE sample size of 1,408 patients was determined on the basis of the power necessary to detect a difference in the primary endpoint of 90-day in-hospital mortality. An important secondary endpoint is the effect of randomization to neuromuscular blockade on long-term outcomes, including post-traumatic stress (PTS)-like symptoms. There are multiple instruments available to assess PTS-like symptoms, with no simple consensus as to which is best (2-4). Among potential instruments considered for ROSE, the Impact of Event Scale-Revised (IES-R) had a higher sensitivity in a published validation study, whereas the PostTraumatic Stress Symptoms instrument (PTSS-14) had a reported higher specificity and lower implementation burden based on its fewer number of questions.
Because it was unclear how to balance these differences in measurement properties when choosing an instrument for the ROSE trial, the present study's aim was to determine whether either of the available instruments offers superior power to detect differences in PTS symptoms across study arms over a plausible range of symptom rates. Because the sample size of a clinical trial is determined on the basis of its power to detect important differences in the primary endpoint, we hypothesized that the selection of an instrument to detect statistically significant differences in an important endpoint could be guided on the basis of each instrument's power to detect potential differences in the endpoint.
Methods Case Study: Reevaluation of Systemic Early Neuromuscular Blockade Randomized Clinical Trial
The motivation for this investigation was the planning of the ROSE RCT, which began enrolling patients in January 2016 (1) . In this trial, patients with moderate to severe ARDS are randomized to either cisatracurium besylate bolus 15 mg, followed by a continuous infusion of 37.5 mg/h for 48 hours or no routine early neuromuscular blockade. While 90-day in-hospital mortality is the study ' There is no single best strategy for measuring the development of PTS-like symptoms. The diagnosis of post-traumatic stress disorder (PTSD) in ICU patients is a subject of a nuanced literature; we have simplified it here to focus our discussion on the general issue of selecting secondary endpoints. In general, a formal diagnosis of PTSD is made by a trained clinician, often using the Clinically Administered PTSD Scale (CAPS), which can take up to 45 minutes to administer (8) .
Our literature review identified two promising telephone questionnaires that had been evaluated in ICU patients. Both used reasonable references for assessing a serious burden of symptoms consistent with PTSD, which is the outcome the RCT is ultimately seeking to measure. (Because PTSD is a clinical diagnosis, we speak here of significant or burdensome PTS-like symptoms.) The IES-R is a 22-item instrument with a reported sensitivity of 100% and specificity of 85% in a critically ill population at the recommended diagnostic threshold (2) . The PTSS-14 is a 14-item instrument with a reported sensitivity of 86% and specificity of 97% in a critically ill population (3) . An instrument's sensitivity is its ability to correctly identify all patients who develop a condition, whereas its specificity is its ability to correctly identify all patients without the condition.
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In a clinical trial, shorter instruments are advantageous because they are less costly to administer and require less respondent burden, holding all else equal. Yet, it was unclear how to trade off these measurement characteristics, given the ultimate goal of the RCT, which is to detect significant differences in the outcome between study arms, should such differences truly exist.
Power Calculations for Reevaluation of Systemic Early Neuromuscular Blockade Secondary Endpoint
The ROSE trial primary endpoint power calculation assumed a 32% 90-day mortality in the control arm. After accounting for early mortality and loss to follow-up, we estimated that approximately 1,000 patients out of the original 1,408 would be interviewed after discharge. We further simplified the present analysis by assuming that an equal number of patients would be interviewed at follow-up in each arm (n = 500). Best estimates of rates of PTS-like symptoms vary widely in the literature. A systematic review and meta-analysis reported prevalence rates of 4-52% across studies, and a pooled prevalence of 22% (9, 10). However, prevalence estimates do not typically adjust for the imperfect measurement characteristics of the various instruments used in these studies (11) . Given the range of clinically significant PTS-like symptoms reported in the literature, we assumed a 25% rate of serious symptoms for our primary calculation, but we also examined a low estimate of 10% and a high estimate of 50% to test whether the results were sensitive to this unknown parameter.
After assuming the rate of clinical significant symptoms was 25% in the control arm, we examined scenarios of increasing symptom rates in the treatment arm and created power curves of each instrument's ability (at the recommended diagnostic threshold) to detect a difference in symptoms between trial arms. Because PTSlike symptoms must be measured using an instrument with imperfect measurement characteristics, the relationship between a true rate and an observed rate (as measured by the instrument) can be determined when the instrument's sensitivity and specificity are known:
where p true represents the true rate and p obs represents the observed rate of a binary outcome (11) . Additionally, the true difference in rates between two groups is related to the observed difference by the following equation (12): Figure 1 . Comparison of the ability of the Post-Traumatic Stress Symptoms instrument (PTSS-14) and the Impact of Events Scale-Revised (IES-R) to detect a difference in post-traumatic stress-like symptoms between study arms. The PTSS-14 is a 14-item instrument with a reported sensitivity of 86% and specificity of 97% for detecting post-traumatic stress-like symptoms in patients recovering from critical illness. The IES-R is a 22-item instrument with a reported sensitivity of 100% and specificity of 85% for detecting post-traumatic stress-like symptoms in patients recovering from critical illness. A 25% baseline symptom rate was assumed in the control arm, and an increased level was assumed in the treatment arm.
Power calculations assume a 500-patient sample size in each arm; the true test characteristics of each instrument were assumed to be the reported point estimates of the sensitivity and specificity of each instrument in its validation studies, and test performance would be similar over the course of the trial. Comparison of the ability of the Post-Traumatic Stress Symptoms instrument (PTSS-14) and the Impact of Events Scale-Revised (IES-R) to detect a difference in post-traumatic stress-like symptoms between study arms when the IES-R's threshold is raised to improve its specificity. The PTSS-14 is a 14-item instrument with a reported sensitivity of 86% and specificity of 97% for detecting post-traumatic stress-like symptoms in patients recovering from critical illness. The IES-R is a 22-item instrument with a reported sensitivity of 75% and specificity of 92% in intensive care unit patients for detecting post-traumatic stress-like symptoms when using a higher diagnostic threshold. A 25% baseline symptom rate was assumed in the control arm, and an increased level was assumed in the treatment arm. Power calculations assume a 500-patient sample size in each arm; the true test characteristics of each instruments were assumed to be the reported point estimates of the sensitivity and specificity of each instrument in its validation studies, and test performance would be similar over the course of the trial.
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Using u ¼ ðspecificity 1 sensitivity 2 1Þ for simplicity, we can say that D obs ¼ D true $u and p obs ¼ ð1 2 specificityÞ 1 p true $u. Using these formulas, one can calculate p obs for each group and then calculate the power to detect a difference in proportions using standard statistical software. We calculated the power to detect a difference in rates between trial arms, given a sample size of 500 in each arm, the sensitivity and specificity of the instrument, and the underlying true event rates in each arm.
Derivation of Power Calculation and Visualization
Power calculations were performed using Stata software (version 14; StataCorp, College Station, TX); the code is provided as an appendix in the online supplement. We also derived a general formula using Mathematica software (version 10; Wolfram Research, Champaign, IL). To visualize the relationship between the sensitivity and specificity of an instrument and the power to detect a difference between two groups, we created three-dimensional surface plots in MATLAB (version 8.6; MathWorks, Inc., Natick, MA).
Human Subjects
We used no individual patient data for these analyses, so this study did not require human subjects or ethics review. The manuscript of this article was approved by the U.S. National Heart, Lung, and Blood Institute (NHLBI) Prevention and Early Treatment of Acute Lung Injury Network publications committee.
Results

Power Calculations for Secondary Outcomes in Reevaluation of Systemic Early Neuromuscular Blockade
If study patients had a 25% rate of PTS-like symptoms, the IES-R would be expected to measure a 36% symptom rate because of its lower specificity, leading to a high number of false positives. Conversely, the PTSS-14 would measure a 23% symptom rate because of its higher specificity and lower number of false positives. Figure 1 displays the power of each instrument to measure a significant difference in symptom rates between treatment arms if a difference of a given magnitude was truly present (i.e., the power of the trial for this secondary endpoint). The analysis assumes a 25% symptom rate in the control arm and an increasing level of symptoms in the treatment arm, with other assumptions described in the Figure 1 legend. As illustrated in the figure, the two instruments provide similar power when the baseline post-traumatic symptom rate is 25%.
However, if the underlying rate of symptoms in the control arm were 10%, the PTSS-14 would perform better, able to detect an 8% absolute difference in rate of significant symptoms between arms (10% in the control arm and 18% in the treatment arm) at 80% power. At the same underlying rate of symptoms, the IES-R would detect only a 10% absolute difference in symptoms at the same power (10% in control and 20% in treatment). If the baseline rate of symptoms were 50%, the two instruments would perform equivalently, both able to detect an 11% absolute difference in the symptom rates at 80% power (50% in the control arm and 61% in the treatment arm). The analysis demonstrates that an instrument with high specificity, rather than high sensitivity, is better suited to detecting differences in rates between trial arms when event rates are low.
Recognizing the importance of an instrument's specificity for overall power, A simplified version of the power calculations for comparing event rates in two arms of a clinical trial, with a two-side alpha of 0.05 is:
p 1 and p 2 are the event rates in each arm, F is the standard normal cumulative distribution function, s 2 p1 2 p2 is the variance of the sample difference, and n is the number of patients in each arm. When p 1 and p 2 are measured with imperfect sensitivity (sn) and specificity (sp), observed event rates and true events rate are related as follows: 
To express power as a function of the true average event rate, p true , and true difference in rates, D true , substitute p true 2 D true =2 and p true 1 D true =2 for p 1true and p 2true respectively into (2), which yields:
Substituting (3), (4) and (5) into the original power formula (1) yields:
Where n is the sample size per group, V F is the variance factor, which substitutes for variance given the imperfect sensitivity (sn) and specificity (sp) of the measurement instrument, and u ¼ sp 1 sn 2 1:
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we also investigated the performance of the IES-R when there is a higher diagnostic threshold for detecting significant PTS symptoms. As reported in the validation study, when the IES-R was set to a higher threshold, its specificity increased to 92%, whereas its sensitivity decreased to 75%. However, at this higher threshold, the analysis showed how the IES-R still did not perform better than the PTSS-14 at detecting differences between trial arms ( Figure 2 ). We also considered the scenario where the treatment arm's mortality rate was lower than the control arm, leading to more patients being available for follow-up in the treatment arm. In this scenario, we found there was substantial difference in the two instruments' abilities to detect PTS symptoms compared with the scenario of equal mortality and follow-up (see Figure E1 in the online supplement).
Derivation of a General Formula for Estimating Power with an Imperfect Measurement Instrument
We show a mathematical derivation of a general formula for estimating power when outcome rates are measured with imperfect sensitivity and specificity in the text box. Table 1 further explains the abbreviations used in this derivation. The derived equation expresses power as a function of the average event rate (e.g., overall prevalence), the true difference between groups, sample size, and the measurement characteristics of the instrument (sensitivity and specificity).
Visualizing the Derived Power Formula
The general formula derived in the text box allows one to calculate the power to detect a true difference in outcome rates when such rates are measured imperfectly, and to compare the power of two instruments to detect this difference, each with a different sensitivity and specificity. In Figure 3 , we graphically illustrate the relationship between sensitivity, specificity, and trial power at varying underlying event rates. For this analysis, we assume that the true absolute difference in the event rates between control and experimental groups was 20%. The underlying event rate had a notable effect on the relationship between sensitivity, specificity, and power. When the prevalence is low, as in the case of Figure 3A , where the event rate is 10% in the control group and 30% in the treatment group, specificity is more important than sensitivity for overall power. If the specificity remains near 100%, power is maintained even as sensitivity drops to as low as 40%, whereas when sensitivity is maintained near 100%, power drops more quickly as specificity declines. This relationship is reversed at higher event rates, as shown in Figure 3C , where the event rate is 50% in the control group and 70% in the treatment group. In this case, if sensitivity remains near 100%, power is better maintained as specificity decreases.
Discussion
In this analysis, we show how clinical study power is a function of the measurement characteristics of the instrument (i.e., sensitivity and specificity) used to assess an outcome and the underlying outcome rate itself. We also show how the selection of an instrument in a clinical trial may be guided on the basis of each instrument's potential power to detect important differences in outcomes between study arms. We used this approach to guide instrument selection for use in an RCT of early muscular blockade in ARDS, finding that the PTSS-14 may potentially provide higher power than the IES-R to detect significant differences in the rate of significant or burdensome PTS-like symptoms in this trial. As such, ROSE will use the shorter instrument, the PTSS-14, because the PTSS-14 will perform equivalently or better over the range of PTS-like symptom rates likely to be encountered during the study while minimizing respondent burden.
In clinical practice, when a clinician chooses a test to evaluate a patient for a specific disease, this choice is guided by balancing the risk associated with missing the disease or falsely diagnosing a disease and exposing the patient to an unnecessary treatment. When the condition cannot be missed or the treatment is not too burdensome, a test with high sensitivity is generally favored. When the condition is more benign or the treatment is more burdensome, a test with high specificity might be favored. For PTS symptoms, a test with high sensitivity might be preferred because of its clinical importance.
The goal of a clinical trial is to determine whether the risk-to-benefit ratio of one treatment is significantly different from that of another, which is different from the clinician's bedside task. Therefore, the selection of a test or instrument to use in a trial should be based on its ability to detect potential differences. When more than one instrument is available to measure an endpoint, our analysis shows how instrument selection can be guided by comparing each instrument's potential ability to detect these differences. When one instrument has both higher sensitivity and higher specificity, that instrument will clearly have higher power. When one instrument has higher sensitivity while the other has higher specificity, specificity tends to be more important than sensitivity for overall power when the prevalence of the event of interest is low. This may be somewhat contrary to clinical practice, where an instrument with high sensitivity may be favored because it would be less likely to miss patients who develop PTSD. Yet, at a certain point, even with very high specificity, an instrument with low sensitivity can still bring down clinical trial power if the sensitivity is so low that no true events are detected. Thus, the analytic Sample variance of the difference in event rates u Specificity 1 sensitivity 2 1 VF Variance factor, which is s Event rate 25% and 45% B Figure 3 . Statistical power to measure a 20% absolute difference in the rate of an outcome across varying instrument sensitivity and specificity, and underlying outcome prevalence. (A) Outcome rate of 10% in control group and 30% in treatment group, (B) outcome rate of 25% in control group and 45% in treatment group, and (C) outcome rate of 50% in control group and 70% in treatment group.
ORIGINAL RESEARCH approach we describe can be used to compare candidate instruments and examine these trade-offs when one has higher sensitivity while the other has higher specificity. This approach may be of interest to others designing RCTs or seeking to maximize the power of cohort studies whose sample size is fixed. Good research practice seeks to estimate the plausible effect size for the primary endpoint on the basis of information in the literature and minimal clinically significant differences (whether in continuous scales or above a diagnostic threshold). This estimate guides calculation of the sample size necessary to detect such an effect size. Explicitly considering the impact of imperfect outcome detection can also maximize the power of the trial and lessen the risk of missing an important difference in an endpoint that could also tip the balance of the risk-to-benefit ratio for a particular treatment. The logic developed here for maximizing the power of secondary outcomes could also inform primary outcome selection when sample size is fixed for other pragmatic reasons; improving the reliability of all measurements in an RCT may substantially improve overall power (13) .
Our analysis also serves as a reminder of the importance of accounting for imperfect measurement when interpreting observations more generally. In our case study, the two instruments considered were predicted to measure outcome rates of 23% and 36%-a more than 50% relative difference-when the true underlying rate was 25%. This may help to explain the wide range of prevalence estimates of long-term outcomes across different cohort studies when different instruments are used (9) . Adjustment for the imperfect measurement characteristics of an instrument could be done to improve the accuracy and comparability of studies, particularly systematic reviews. However, such an adjustment depends on whether the estimated sensitivity and specificity of tests are correct. The present analysis also depends on this assumption. Validation studies of tests cannot estimate a test's characteristics perfectly and necessarily report confidence intervals surrounding these estimates.
In the present analysis, we made the simplifying assumption that the point estimate of each instrument's sensitivity and specificity as reported in the validation studies represented the true test characteristics. We did not attempt to account for the confidence intervals surrounding the sensitivity and specificity estimates. In future work, researchers could consider ways of incorporating confidence intervals from different validation samples to ensure that the most relevant measurement characteristics are incorporated.
In our primary analysis, we assumed that there would be no difference in mortality or availability for follow-up between trial arms. In our supplemental analysis, we evaluated the effect of unequal sample size between groups due to differences in mortality, and we assumed that mortality does not provide information about (and is uncorrelated with) rates of secondary outcome. Although a difference in a clinical trial's primary outcome may make secondary outcomes appear less important, there still may be the real possibility that a treatment provides benefit to some patients but also causes harm through a different mechanism (a form of treatment effect heterogeneity) (14) . Thus, making measurement of differences in secondary outcomes as accurate as possible ORIGINAL RESEARCH is always of critical importance when quantifying the particular risks and benefits of a specific therapy for individual patients. This work has additional limitations that may make the analysis not applicable to all scenarios. If the sensitivity and specificity of an instrument are not known in a population under study, the analysis is not feasible. Recent efforts to measure the psychometrics of commonly used instruments in critical care populations are therefore particularly important (2, (15) (16) (17) . If the secondary outcome does not require a measurement instrument (e.g., reintubation), this type of analysis would also be unnecessary. If instruments give a continuous score that should not be dichotomized, the analytic approach to determining the best instrument would also be different. We chose to dichotomize the PTS syndrome endpoint, which both simplified the analysis and made it more interpretable. An alternative approach would be to keep the PTS symptom measures on a continuous scale and compare mean scores between groups. This approach may improve the power to detect small differences in symptom levels between trial arms. However, by dichotomizing this outcome, we focus here on detecting clinically significant differences across a burden threshold, a common approach to diagnosis.
Optimizing the measurement of any specific secondary endpoint does not diminish the risks of making a false discovery when performing multiple comparisons across multiple secondary endpoints. We suggest using a structured approach to manage the potential for false discoveries rather than haphazardly diluting the power of a secondary endpoint that has substantial clinical importance (18) . Finally, the derivation of the general formula for power in this specific context relies extensively on well-established principles of statistics; no claim of substantial statistical originality is made. Our contribution in this work is to examine implications for planning of RCTs.
Conclusions
The power of an RCT to detect differences in secondary outcomes depends not only on the true effect of the treatment under study but also on the underlying outcome rates and measurement characteristics of the measurement instrument. Selecting instruments for use during an RCT can be guided by maximizing this power. Doing so ensures that the unique opportunity afforded by an RCT will yield the greatest increase in scientific knowledge. n Author disclosures are available with the text of this article at www.atsjournals.org.
